Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IB3D
- Development stage
- Unknown
- Lead developer
- Inflammasome Therapeutics
- Modality
- Small Molecules, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intravitreal
01
Overview
IB3D is a sustained-release intravitreal implant containing Kamuvudine-8 (K8), a small molecule inhibitor of the NLRP3 inflammasome. Developed by Inflammasome Therapeutics, IB3D is designed for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and diabetic macular edema (DME). Kamuvudines represent a novel class of modified nucleosides that lack the 5'-hydroxyl group, which prevents their phosphorylation and subsequent incorporation into DNA, thereby avoiding the mitochondrial and systemic toxicities associated with traditional nucleoside reverse transcriptase inhibitors (NRTIs). By specifically inhibiting the NLRP3 inflammasome, IB3D targets the chronic inflammatory response and subsequent cell death of retinal pigment epithelium (RPE) cells, which are central to the progression of GA. The implant is engineered to provide a steady release of the active drug over a period of several months, reducing the burden of frequent intravitreal injections.
- Other names
- Kamuvudine-8Kamuvudine8Kamuvudine 8K8 sustained-release implantK-8 sustained-release implantK 8 sustained-release implant
Beyond the preview
Go deeper on IB3D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IB3D.